DE60313859D1 - Induktion der anti-tumor-ctl-immunität durch in-vivo-aktivierung von 4-1bb und/oder cd40 - Google Patents

Induktion der anti-tumor-ctl-immunität durch in-vivo-aktivierung von 4-1bb und/oder cd40

Info

Publication number
DE60313859D1
DE60313859D1 DE60313859T DE60313859T DE60313859D1 DE 60313859 D1 DE60313859 D1 DE 60313859D1 DE 60313859 T DE60313859 T DE 60313859T DE 60313859 T DE60313859 T DE 60313859T DE 60313859 D1 DE60313859 D1 DE 60313859D1
Authority
DE
Germany
Prior art keywords
induction
vivo activation
ctl immunity
tumor ctl
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60313859T
Other languages
English (en)
Other versions
DE60313859T2 (de
Inventor
Linda Diehl
Mierlo Geertje Van
Cornelis J Melief
Rene Toes
Rienk Offringa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leids Universitair Medisch Centrum LUMC
Original Assignee
Leids Universitair Medisch Centrum LUMC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leids Universitair Medisch Centrum LUMC filed Critical Leids Universitair Medisch Centrum LUMC
Publication of DE60313859D1 publication Critical patent/DE60313859D1/de
Application granted granted Critical
Publication of DE60313859T2 publication Critical patent/DE60313859T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/025—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
DE60313859T 2002-04-04 2003-04-04 Induktion der anti-tumor-ctl-immunität durch in-vivo-aktivierung von 4-1bb und/oder cd40 Expired - Lifetime DE60313859T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/115,620 US20030118588A1 (en) 1999-05-22 2002-04-04 Induction of anti-tumor CTL immunity through in vivo triggering of 4-1BB and/or CD40
US115620 2002-04-04
PCT/NL2003/000254 WO2003084999A1 (en) 2002-04-04 2003-04-04 Induction of anti-tumor ctl immunity through in vivo triggering of 4-1bb and/or cd40

Publications (2)

Publication Number Publication Date
DE60313859D1 true DE60313859D1 (de) 2007-06-28
DE60313859T2 DE60313859T2 (de) 2008-01-24

Family

ID=28789826

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60313859T Expired - Lifetime DE60313859T2 (de) 2002-04-04 2003-04-04 Induktion der anti-tumor-ctl-immunität durch in-vivo-aktivierung von 4-1bb und/oder cd40

Country Status (14)

Country Link
US (1) US20030118588A1 (de)
EP (1) EP1490407B1 (de)
JP (1) JP2005538043A (de)
KR (1) KR100717901B1 (de)
CN (1) CN1646566A (de)
AT (1) ATE362491T1 (de)
AU (1) AU2003225431B2 (de)
CA (1) CA2480162C (de)
DE (1) DE60313859T2 (de)
DK (1) DK1490407T3 (de)
ES (1) ES2285157T3 (de)
NZ (1) NZ535729A (de)
SI (1) SI1490407T1 (de)
WO (1) WO2003084999A1 (de)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR039067A1 (es) * 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
US7670604B2 (en) 2002-12-13 2010-03-02 Aurelium Biopharma, Inc. Vimentin directed diagnostics and therapeutics for multidrug resistant neoplastic disease
US7288638B2 (en) 2003-10-10 2007-10-30 Bristol-Myers Squibb Company Fully human antibodies against human 4-1BB
JP2007515924A (ja) * 2003-12-15 2007-06-21 アウレリウム バイオファーマ インク． ビメンチン指向性診断法、および、多剤耐性を示す腫瘍性疾患の治療法
KR20060132006A (ko) 2004-03-23 2006-12-20 비오겐 아이덱 엠에이 아이엔씨. 수용체 커플링제 및 이의 치료적 용도
JP2006265155A (ja) * 2005-03-23 2006-10-05 Link Genomics Kk 癌の免疫療法
DE602006021408D1 (de) 2005-04-27 2011-06-01 Univ Leiden Medical Ct Behandlung von hpv-induzierter intraepithelialer anogenitaler neoplasien
KR100847755B1 (ko) * 2006-03-29 2008-07-22 울산대학교 산학협력단 항-4-1ｂｂ 항체 및 항-ｃｄ4 항체를 포함하는 암 및자가면역질환 치료제 조성물
EP2589654A1 (de) 2006-05-03 2013-05-08 The Regents of the University of Colorado, a body corporate Synergistische Hilfsstoffkombination aus CD40-Agonisten-Antikörper/Typ1-Interferon, diese enthaltende Konjugate und ihre Verwendung als Therapeutika zur Verstärkung der Zellimmunität
GB0620894D0 (en) * 2006-10-20 2006-11-29 Univ Southampton Human immune therapies using a CD27 agonist alone or in combination with other immune modulators
CA2996732C (en) 2007-03-26 2020-10-27 Academisch Ziekenhuis Leiden H.O.D.N. Lumc Prame derived peptides and immunogenic compositions comprising these
EP2468763B1 (de) 2007-05-31 2014-06-18 Academisch Ziekenhuis Leiden h.o.d.n. LUMC HPV-Epitope als Ziel für zervikale Tumoren infiltrierende T-Zellen zur Verwendung bei Impfstoffen
EP2155240B1 (de) 2007-05-31 2014-04-30 Academisch Ziekenhuis Leiden h.o.d.n. LUMC Intradermale hpv-peptidimpfung
CN101796070A (zh) 2007-05-31 2010-08-04 莱顿教学医院 p53肽疫苗
CA2735421A1 (en) * 2008-08-29 2010-03-04 Academisch Ziekenhuis Leiden H.O.D.N. Lumc Delivery of a cd40 agonist to a tumor draining lymph node of a subject
WO2010042433A1 (en) 2008-10-06 2010-04-15 Bristol-Myers Squibb Company Combination of cd137 antibody and ctla-4 antibody for the treatment of proliferative diseases
KR101222587B1 (ko) * 2010-05-04 2013-01-16 고려대학교 산학협력단 재발암, 내성암 또는 암전이 치료용 조성물
EP2614082B1 (de) 2010-09-09 2018-10-03 Pfizer Inc 4-1bb-bindemoleküle
ES2617983T3 (es) * 2011-01-10 2017-06-20 Ct Atlantic Ltd. Terapia de combinación que incluye anticuerpos de unión a antígenos asociados a tumores
CN113461819B (zh) 2011-04-29 2024-01-02 埃派斯进有限公司 抗-cd40抗体及其使用方法
WO2013006050A1 (en) 2011-07-06 2013-01-10 Isa Pharmaceuticals B.V. Peptides inducing or enhancing an immune response against prostate-specific membrane protein (PSMA)
EP2687849A1 (de) 2012-07-20 2014-01-22 ISA Pharmaceuticals B.V Verfahren zur Bereitstellung einer optimierten Immuntherapiezusammensetzung
EP3925977A1 (de) 2012-10-30 2021-12-22 Apexigen, Inc. Anti-cd40-antikörper und verfahren zur verwendung
EP3094652B1 (de) 2014-01-13 2021-09-29 Baylor Research Institute Neuartige impfstoffe gegen hpv und hpv-assoziierte erkrankungen
CA2950863C (en) 2014-06-02 2023-01-17 Isa Pharmaceuticals B.V. Synthetic long peptides (slp) for therapeutic vaccination against hepatitis b virus infection
GB201413665D0 (en) 2014-07-03 2014-09-17 Transimmune Ag And Yale University Method for obtaining globally activated monocytes
US10875926B2 (en) * 2015-09-22 2020-12-29 Dingfu Biotarget Co., Ltd. Fully human antibody against human CD 137
AU2017281389B2 (en) 2016-06-20 2024-02-22 Isa Pharmaceuticals B.V. Formulation of a peptide vaccine
WO2018011421A1 (en) 2016-07-14 2018-01-18 Genmab A/S Multispecific antibodies against cd40 and cd137
CA3069438A1 (en) 2017-07-11 2019-01-17 Compass Therapeutics Llc Agonist antibodies that bind human cd137 and uses thereof
CN111511762A (zh) 2017-08-21 2020-08-07 天演药业公司 抗cd137分子及其用途
WO2019089753A2 (en) 2017-10-31 2019-05-09 Compass Therapeutics Llc Cd137 antibodies and pd-1 antagonists and uses thereof
WO2019100052A2 (en) 2017-11-20 2019-05-23 Compass Therapeutics Llc Cd137 antibodies and tumor antigen-targeting antibodies and uses thereof
WO2019104716A1 (en) * 2017-12-01 2019-06-06 Adagene Inc. Methods for using cd137 ligand as biomarker for treatment with anti-cd137 antibody
WO2019148445A1 (en) 2018-02-02 2019-08-08 Adagene Inc. Precision/context-dependent activatable antibodies, and methods of making and using the same
EP4100051A2 (de) 2020-02-07 2022-12-14 ISA Pharmaceuticals B.V. Behandlung von hpv-assoziierten erkrankungen
WO2022036495A1 (en) 2020-08-17 2022-02-24 Utc Therapeutics Inc. Lymphocytes-antigen presenting cells co-stimulators and uses thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1082141B1 (de) * 1998-05-23 2005-09-14 Leiden university medical center Cd40 bindende antikörper und ctl peptide zur behandlung von tumoren

Also Published As

Publication number Publication date
KR20040098048A (ko) 2004-11-18
CN1646566A (zh) 2005-07-27
US20030118588A1 (en) 2003-06-26
WO2003084999A1 (en) 2003-10-16
DK1490407T3 (da) 2007-08-13
EP1490407B1 (de) 2007-05-16
CA2480162C (en) 2011-07-12
SI1490407T1 (sl) 2007-08-31
EP1490407A1 (de) 2004-12-29
AU2003225431B2 (en) 2006-07-27
ATE362491T1 (de) 2007-06-15
NZ535729A (en) 2008-02-29
AU2003225431A1 (en) 2003-10-20
KR100717901B1 (ko) 2007-05-14
ES2285157T3 (es) 2007-11-16
CA2480162A1 (en) 2003-10-16
DE60313859T2 (de) 2008-01-24
JP2005538043A (ja) 2005-12-15

Similar Documents

Publication Publication Date Title
DE60313859D1 (de) Induktion der anti-tumor-ctl-immunität durch in-vivo-aktivierung von 4-1bb und/oder cd40
IS5993A (is) Blokkerar, skyldir baff og notkun þeirra í örvun og tálmun B-frumna og ónæmisglóbúlína í ónæmissvari
TW200510459A (en) RG1 antibodies and uses thereof
PL374865A1 (en) Treatment of tnf alpha related disorders
ZA200508389B (en) Humanized antibodies to interferon alpha receptor-1(IFNAR-1)
IL211367A0 (en) An antibody, a fragment thereof, a method of preparing the same and a use of the antibody
IL139700A0 (en) Immunotherapeutic composition and method for the treatment of prostate cancer
AU3327701A (en) Humanized anti-ccr2 antibodies and methods of use therefor
ATE212038T1 (de) Humanisierte monoklonale anti-cd40 antikörper und fragmente zur hemmung der b-zellaktivierung
NO20062385L (no) Preparat for behandling av interferonresistente tumorer
ATE509955T1 (de) Humanisierte kollagen-antikörper und damit verbundene verfahren
DE69934515D1 (de) Humanisierte monoklonale integrin antikörper
TW200500377A (en) Method of humanizing immune system molecules
DK1411962T3 (da) Terapi for pancreacancer med monoklonalt stof
EE200500012A (et) Peptiid-pähine passiivne immunoteraapia ateroskleroosi raviks
DE502004006896D1 (de) Derivative von 9,10-Dihydro-9-oxa-10-phosphaphenanthren-10-oxid
WO2005060368A3 (en) Humanized anti-ccr2 antibodies and methods of use
UA96917C2 (ru) Антитела, направленные против пептида бета-амилоида, и способы их применения
UA49653A (uk) Спосіб лікування акантолітичної пухирчатки
DK1366033T3 (da) Kemiske forbindelser
SE0202959D0 (sv) Peptide-Base passive immunization therapy for treatment of atherosclerosis
AU2013204147B2 (en) Treatment of TNFalpha related disorders

Legal Events

Date Code Title Description
8364 No opposition during term of opposition